BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet 1997;350:713-4. [PMID: 9291911 DOI: 10.1016/S0140-6736(05)63513-1] [Cited by in Crossref: 189] [Cited by in F6Publishing: 198] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Wagle A, Goerlich E, Post WS, Woldu B, Wu KC, Hays AG. HIV and Global Cardiovascular Health. Curr Cardiol Rep 2022. [PMID: 35802233 DOI: 10.1007/s11886-022-01741-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Shytaj IL, Procopio FA, Tarek M, Carlon-Andres I, Tang HY, Goldman AR, Munshi M, Kumar Pal V, Forcato M, Sreeram S, Leskov K, Ye F, Lucic B, Cruz N, Ndhlovu LC, Bicciato S, Padilla-Parra S, Diaz RS, Singh A, Lusic M, Karn J, Alvarez-Carbonell D, Savarino A. Glycolysis downregulation is a hallmark of HIV-1 latency and sensitizes infected cells to oxidative stress. EMBO Mol Med 2021;13:e13901. [PMID: 34289240 DOI: 10.15252/emmm.202013901] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
3 Zhang E, Chai JC, Deik AA, Hua S, Sharma A, Schneider MF, Gustafson D, Hanna DB, Lake JE, Rubin LH, Post WS, Anastos K, Brown T, Clish CB, Kaplan RC, Qi Q. Plasma Lipidomic Profiles and Risk of Diabetes: 2 Prospective Cohorts of HIV-Infected and HIV-Uninfected Individuals. J Clin Endocrinol Metab 2021;106:999-1010. [PMID: 33420793 DOI: 10.1210/clinem/dgab011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Shytaj IL, Procopio FA, Tarek M, Carlon-andres I, Tang H, Goldman AR, Munshi M, Forcato M, Leskov K, Ye F, Lucic B, Cruz N, Singh A, Bicciato S, Padilla-parra S, Lusic M, Diaz RS, Alvarez-carbonell D, Savarino A. Glycolysis downregulation is a hallmark of HIV-1 latency and sensitizes infected cells to oxidative stress.. [DOI: 10.1101/2020.12.30.424810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Zhang E, Chai JC, Deik AA, Hua S, Sharma A, Schneider MF, Gustafson D, Hanna DB, Lake JE, Rubin LH, Post WS, Anastos K, Brown T, Clish CB, Kaplan RC, Qi Q. Plasma lipidomic profiles and risk of diabetes: two prospective cohorts of HIV-infected and HIV-uninfected individuals.. [DOI: 10.1101/2020.11.11.20229351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Bani SB, Danquah KO, Obirikorang C, Owiredu WKBA, Quaye L, Muonir Der E, Acheampong E, Adams Y, Dapare PPM, Banyeh M, Anto EO, Sakyi SA. Single nucleotide polymorphisms in LCAT may contribute to dyslipidaemia in HIV-infected individuals on HAART in a Ghanaian population. Sci Rep 2020;10:19419. [PMID: 33173066 DOI: 10.1038/s41598-020-76113-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Callender LA, Curran M, Bates SM, Mairesse M, Weigandt J, Betts CJ. The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. Front Immunol 2020;11:1991. [PMID: 32903476 DOI: 10.3389/fimmu.2020.01991] [Cited by in Crossref: 70] [Cited by in F6Publishing: 75] [Article Influence: 23.3] [Reference Citation Analysis]
8 Chang CY, Whitt K, Liu Z, Caldwell SH. The Liver and Insulin Resistance: The Important Convergence of Endocrinology and Hepatology. Contemporary Endocrinology 2020. [DOI: 10.1007/978-3-030-25057-7_13] [Reference Citation Analysis]
9 Lau JSY, Smith MZ, Lewin SR, McMahon JH. Clinical trials of antiretroviral treatment interruption in HIV-infected individuals. AIDS 2019;33:773-91. [PMID: 30883388 DOI: 10.1097/QAD.0000000000002113] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
10 Noubissi EC, Katte JC, Sobngwi E. Diabetes and HIV. Curr Diab Rep 2018;18:125. [PMID: 30294763 DOI: 10.1007/s11892-018-1076-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
11 Samaras K. Endocrine and Metabolic Emergencies in HIV/AIDS. Endocrine and Metabolic Medical Emergencies 2018. [DOI: 10.1002/9781119374800.ch8] [Reference Citation Analysis]
12 Willig AL, Overton ET. Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence. Curr HIV/AIDS Rep 2016;13:289-96. [PMID: 27541600 DOI: 10.1007/s11904-016-0330-z] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 12.3] [Reference Citation Analysis]
13 Kobayashi N, Nakahara M, Oka M, Saeki K. Additional attention to combination antiretroviral therapy-related lipodystrophy. World J Virol 2017; 6(3): 49-52 [PMID: 28868242 DOI: 10.5501/wjv.v6.i3.49] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
14 Iwata K, Ogawa W. Reversible diabetes mellitus induced by use of, and improved after discontinuation of, the antiretroviral medication zidovudine: a case report. J Med Case Rep 2017;11:157. [PMID: 28610599 DOI: 10.1186/s13256-017-1326-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Steiniche D, Jespersen S, Erikstrup C, Krarup H, Handberg A, Østergaard L, Haraldsdottir T, Medina C, Gomes Correira F, Laursen AL, Bjerregaard-Andersen M, Wejse C, Hønge BL; Bissau HIV Cohort study group. Diabetes mellitus and impaired fasting glucose in ART-naïve patients with HIV-1, HIV-2 and HIV-1/2 dual infection in Guinea-Bissau: a cross-sectional study. Trans R Soc Trop Med Hyg 2016;110:219-27. [PMID: 27076509 DOI: 10.1093/trstmh/trw017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yalamanchi S, Brown T, Dobs A. HIV Infection and Diabetes. Principles of Diabetes Mellitus 2017. [DOI: 10.1007/978-3-319-18741-9_38] [Reference Citation Analysis]
17 Yalamanchi S, Brown T, Dobs A. HIV Infection and Diabetes. Principles of Diabetes Mellitus 2016. [DOI: 10.1007/978-3-319-20797-1_38-1] [Reference Citation Analysis]
18 Lebovitz HE. Hyperglycemia Secondary to Nondiabetic Conditions and Therapies. Endocrinology: Adult and Pediatric 2016. [DOI: 10.1016/b978-0-323-18907-1.00042-1] [Reference Citation Analysis]
19 Hejazi N, Rajikan R. Metabolic Abnormalities in HIV-Infected Populations without or with Antiretroviral Therapy (ART). Health of HIV Infected People 2015. [DOI: 10.1016/b978-0-12-800769-3.00002-0] [Reference Citation Analysis]
20 Sitole L, Steffens F, Krüger TP, Meyer D. Mid-ATR-FTIR spectroscopic profiling of HIV/AIDS sera for novel systems diagnostics in global health. OMICS 2014;18:513-23. [PMID: 24937213 DOI: 10.1089/omi.2013.0157] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
21 Murphy CS, Mckay GA. HIV and diabetes. Diabetes Management 2013;3:495-503. [DOI: 10.2217/dmt.13.52] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
22 Bajaj S, Tyagi SK, Bhargava A. Metabolic syndrome in human immunodeficiency virus positive patients. Indian J Endocrinol Metab 2013;17:117-20. [PMID: 23776863 DOI: 10.4103/2230-8210.107821] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
23 Samaras K. The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. Curr HIV/AIDS Rep. 2012;9:206-217. [PMID: 22752405 DOI: 10.1007/s11904-012-0124-x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 5.9] [Reference Citation Analysis]
24 Rasmussen LD, Mathiesen ER, Kronborg G, Pedersen C, Gerstoft J, Obel N. Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study. PLoS One 2012;7:e44575. [PMID: 22984529 DOI: 10.1371/journal.pone.0044575] [Cited by in Crossref: 87] [Cited by in F6Publishing: 96] [Article Influence: 7.9] [Reference Citation Analysis]
25 Ihenetu K, Mason D. Biochemical Manifestation of HIV Lipodystrophy Syndrome. Int J MCH AIDS 2012;1:92-101. [PMID: 27621962 DOI: 10.21106/ijma.6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Hughes CA, Cashin RP, Eurich DT, Houston S. Risk factors for new-onset diabetes mellitus in patients receiving protease inhibitor therapy. Can J Infect Dis Med Microbiol 2005;16:230-2. [PMID: 18159550 DOI: 10.1155/2005/971971] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
27 Taylor SA, Lee GA, Pao VY, Anthonypillai J, Aweeka FT, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. J Acquir Immune Defic Syndr 2010;55:361-4. [PMID: 20595906 DOI: 10.1097/QAI.0b013e3181e6a7d9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
28 Seaberg EC, Benning L, Sharrett AR, Lazar JM, Hodis HN, Mack WJ, Siedner MJ, Phair JP, Kingsley LA, Kaplan RC. Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke. 2010;41:2163-2170. [PMID: 20798374 DOI: 10.1161/strokeaha.110.583856] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 4.8] [Reference Citation Analysis]
29 Rao MN, Mulligan K, Schambelan M. HIV Infection and Diabetes. Principles of Diabetes Mellitus 2010. [DOI: 10.1007/978-0-387-09841-8_38] [Reference Citation Analysis]
30 Lebovitz HE. Hyperglycemia Secondary to Nondiabetic Conditions and Therapies. Endocrinology 2010. [DOI: 10.1016/b978-1-4160-5583-9.00043-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Samaras K. How sweet it is? Susceptibility to diabetes mellitus in HIV-1 treatment. HIV Therapy 2009;3:613-624. [DOI: 10.2217/hiv.09.46] [Reference Citation Analysis]
32 Flint OP, Noor MA, Hruz PW, Hylemon PB, Yarasheski K, Kotler DP, Parker RA, Bellamine A. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol 2009;37:65-77. [PMID: 19171928 DOI: 10.1177/0192623308327119] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 4.5] [Reference Citation Analysis]
33 Chang CY, Whitt K, Liu Z, Caldwell SH. The Liver and Insulin Resistance: The Important Convergence of Endocrinology and Hepatology. Insulin Resistance. [DOI: 10.1007/978-1-59745-192-5_13] [Reference Citation Analysis]
34 Grunfeld C, Kotler DP, Arnett DK, Falutz JM, Haffner SM, Hruz P, Masur H, Meigs JB, Mulligan K, Reiss P, Samaras K; Working Group 1. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 2008;118:e20-8. [PMID: 18566314 DOI: 10.1161/CIRCULATIONAHA.107.189623] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 3.1] [Reference Citation Analysis]
35 Lien LF, Lane JD. Pharmacologic Factors Affecting Glycemic Control. Type 2 Diabetes Mellitus. [DOI: 10.1007/978-1-60327-043-4_29] [Reference Citation Analysis]
36 Simha V, Garg A. Atypical Forms of Type 2 Diabetes. Type 2 Diabetes Mellitus. [DOI: 10.1007/978-1-60327-043-4_27] [Reference Citation Analysis]
37 Greenblatt R, Tien P. The Endocrine System. HIV and Aging 2008. [DOI: 10.3109/9781420065985-6] [Reference Citation Analysis]
38 Mccullen M, Ahmed I. Drug-Induced Hyperglycemia and Diabetes Mellitus. Type 2 Diabetes 2007. [DOI: 10.3109/9780849379581-35] [Reference Citation Analysis]
39 Simha V, Agarwal AK. Inherited and Acquired Lipodystrophies. Nutrition and Health. [DOI: 10.1007/978-1-59745-370-7_18] [Reference Citation Analysis]
40 Lee GA, Rao M, Mulligan K, Lo JC, Aweeka F, Schwarz JM, Schambelan M, Grunfeld C. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS 2007;21:2183-90. [PMID: 18090045 DOI: 10.1097/QAD.0b013e32826fbc54] [Cited by in Crossref: 51] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
41 Ohara T. Diabetes. Cachexia and Wasting: A Modern Approach. [DOI: 10.1007/978-88-470-0552-5_28] [Reference Citation Analysis]
42 Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, Young M, Justman JE. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007;21:1739-45. [PMID: 17690572 DOI: 10.1097/QAD.0b013e32827038d0] [Cited by in Crossref: 136] [Cited by in F6Publishing: 145] [Article Influence: 8.5] [Reference Citation Analysis]
43 Mehandru S, Vcelar B, Wrin T, Stiegler G, Joos B, Mohri H, Boden D, Galovich J, Tenner-Racz K, Racz P, Carrington M, Petropoulos C, Katinger H, Markowitz M. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol 2007;81:11016-31. [PMID: 17686878 DOI: 10.1128/JVI.01340-07] [Cited by in Crossref: 93] [Cited by in F6Publishing: 98] [Article Influence: 5.8] [Reference Citation Analysis]
44 Florescu D, Kotler DP. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antivir Ther 2007;12:149-62. [PMID: 17503657 DOI: 10.1177/135965350701200214] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
45 Ngondi Jud L, . SE, . MF, . HY, . JO. Lipid Profile of Infected Patients Treated with Highly Active Antiretroviral Therapy in Cameroon. J of Medical Sciences 2007;7:670-673. [DOI: 10.3923/jms.2007.670.673] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
46 Karen S, Witold R, Cholewińska G. Physiotherapy of patients with lipodystrophy associated with HAART. HIV & AIDS Review 2007;6:20-22. [DOI: 10.1016/s1730-1270(10)60037-9] [Reference Citation Analysis]
47 Calza DL, Manfredi R, Chiodo F. Cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Expert Opinion on Therapeutic Patents 2006;16:1497-516. [DOI: 10.1517/13543776.16.11.1497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 de Larrañaga GF, Wingeyer SD, Puga LM, Alonso BS, Benetucci JA. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment. Eur J Clin Microbiol Infect Dis 2006;25:98-103. [PMID: 16477441 DOI: 10.1007/s10096-006-0090-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
49 Dreimane D, Geffner ME. Endocrine disorders. Handbook of Pediatric HIV Care 2006. [DOI: 10.1017/cbo9780511544781.030] [Reference Citation Analysis]
50 Rao MN, Lee GA, Grunfeld C. Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors. Am J Infect Dis 2006;2:159-66. [PMID: 22162956 DOI: 10.3844/ajidsp.2006.159.166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
51 Dubé MP, Parker RA, Tebas P, Grinspoon SK, Zackin RA, Robbins GK, Roubenoff R, Shafer RW, Wininger DA, Meyer WA 3rd, Snyder SW, Mulligan K. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005;19:1807-18. [PMID: 16227788 DOI: 10.1097/01.aids.0000183629.20041.bb] [Cited by in Crossref: 156] [Cited by in F6Publishing: 159] [Article Influence: 8.7] [Reference Citation Analysis]
52 Lien LF, Feinglos MN. Protease inhibitor-induced diabetic complications : incidence, management and prevention. Drug Saf 2005;28:209-26. [PMID: 15733026 DOI: 10.2165/00002018-200528030-00003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
53 Ertekin V, Selimoğlu MA, Orbak Z. Effects of lamivudine therapy on the glucose metabolism in children with chronic hepatitis B: first year follow-up results. Eur J Gastroenterol Hepatol 2005;17:655-9. [PMID: 15879728 DOI: 10.1097/00042737-200506000-00010] [Reference Citation Analysis]
54 Dreimane D, Geffner ME. Endocrine disorders. Textbook of Pediatric HIV Care 2005. [DOI: 10.1017/cbo9780511544798.038] [Reference Citation Analysis]
55 Levy AR, McCandless L, Harrigan PR, Hogg RS, Bondy G, Iloeje UH, Mukherjee J, Montaner JS. Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. Lipids Health Dis 2005;4:4. [PMID: 15705191 DOI: 10.1186/1476-511X-4-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
56 Antiretroviral Drugs to Treat Human Immunodeficiency Virus Infections. Antiviral Agents, Vaccines, and Immunotherapies 2004. [DOI: 10.1201/b14238-3] [Reference Citation Analysis]
57 Schwarz JM, Lee GA, Park S, Noor MA, Lee J, Wen M, Lo JC, Mulligan K, Schambelan M, Grunfeld C. Indinavir increases glucose production in healthy HIV-negative men. AIDS 2004;18:1852-4. [PMID: 15316349 DOI: 10.1097/00002030-200409030-00017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.4] [Reference Citation Analysis]
58 Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003;63:2555-74. [PMID: 14636077 DOI: 10.2165/00003495-200363230-00001] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 3.5] [Reference Citation Analysis]
59 Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, Mulligan K, Schambelan M, Grunfeld C. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004;18:641-9. [PMID: 15090769 DOI: 10.1097/00002030-200403050-00008] [Cited by in Crossref: 141] [Cited by in F6Publishing: 147] [Article Influence: 7.4] [Reference Citation Analysis]
60 Lee JC. Altered Glucose Metabolism in HIV-infected Patients Treated With HAART. Journal of Pharmacy Practice 2004;17:80-86. [DOI: 10.1177/0897190003261313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
61 Aschkenazi S, Rochelson B, Bernasko J, Kaplan J. Insulin Resistance Complicating Pregnancy in a Human Immunodeficiency Virus–Infected Patient Treated With Protease Inhibitors and Corticosteroids. Obstetrics & Gynecology 2003;102:1210-1212. [DOI: 10.1097/00006250-200311001-00032] [Reference Citation Analysis]
62 Garg A, Misra A. Lipodystrophies and Diabetes. International Textbook of Diabetes Mellitus 2003. [DOI: 10.1002/0470862092.d0509] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
63 Galli M, Ridolfo AL, Adorni F, Cappelletti A, Morelli P, Massetto B, Piazza M, Gianelli E, Vaccarezza M, Gervasoni C, Moroni M. Correlates of Risk of Adipose Tissue Alterations and Their Modifications over Time in HIV-1-Infected Women Treated with Antiretroviral Therapy. Antiviral Therapy 2003;8:347-354. [DOI: 10.1177/135965350300800412] [Reference Citation Analysis]
64 Fantoni M, Del Borgo C, Autore C. Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2003;17 Suppl 1:S162-9. [PMID: 12870543 DOI: 10.1097/00002030-200304001-00020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
65 Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003;17:S141-8. [DOI: 10.1097/00002030-200304001-00017] [Cited by in Crossref: 173] [Cited by in F6Publishing: 177] [Article Influence: 8.7] [Reference Citation Analysis]
66 Orfanos CE, Garbe C. HIV-Infektion und Kaposi-Sarkom. Therapie der Hautkrankheiten 2002. [DOI: 10.1007/978-3-642-56219-8_44] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
67 Schooley RT, Benson CA. Pathogenesis and Clinical Manifestations of HIV-1 Infection. Clinical Approach to Infection in the Compromised Host 2002. [DOI: 10.1007/0-306-47527-8_12] [Reference Citation Analysis]
68 Keithley JK. CONTINUING EDUCATION OFFERING. Journal of the Association of Nurses in AIDS Care 2001;12:67-74. [DOI: 10.1016/s1055-3290(06)60160-x] [Reference Citation Analysis]
69 Rosenfeld CR, Reddy, SSK. Endocrine and Metabolic Manifestations of HIV Infection and AIDS. J Intensive Care Med 2001;16:161-168. [DOI: 10.1046/j.1525-1489.2001.00161.x] [Reference Citation Analysis]
70 Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, Rhodes PH, Wood KC, Holmberg SD; HIV Outpatient Study Investigators. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;15:1389-98. [PMID: 11504960 DOI: 10.1097/00002030-200107270-00008] [Cited by in Crossref: 326] [Cited by in F6Publishing: 282] [Article Influence: 14.8] [Reference Citation Analysis]
71 Rosenfeld CR, Reddy SSK. Endocrine and Metabolic Manifestations of HIV Infection and AIDS. J Intensive Care Med 2001;16:161-168. [DOI: 10.1177/088506660101600401] [Reference Citation Analysis]
72 Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001;15:F11-8. [PMID: 11399973 DOI: 10.1097/00002030-200105040-00001] [Cited by in Crossref: 238] [Cited by in F6Publishing: 249] [Article Influence: 10.8] [Reference Citation Analysis]
73 John M, Nolan D, Mallal S. Antiretroviral Therapy and the Lipodystrophy Syndrome. Antiviral Therapy 2001;6:9-20. [DOI: 10.1177/135965350100600102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
74 Kanmaz TJ, Lee NJ. Significant Toxicities Associated with Antiretroviral Therapy. Journal of Pharmacy Practice 2000;13:457-474. [DOI: 10.1106/2uu8-8jjd-uhru-c14r] [Reference Citation Analysis]
75 Behrens GM, Stoll M, Schmidt RE. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf. 2000;23:57-76. [PMID: 10915032 DOI: 10.2165/00002018-200023010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Behrens GM, Stoll M, Schmidt RE. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf 2000;23:57-76. [PMID: 10915032 DOI: 10.2165/00002018-200023010-00004] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 3.3] [Reference Citation Analysis]
77 Plosker GL, Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs 1999;58:1165-203. [PMID: 10651394 DOI: 10.2165/00003495-199958060-00011] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 2.8] [Reference Citation Analysis]
78 Little R, Yarchoan R. Considerations in the Management of HIV Infection in Patients Undergoing Antineoplastic Chemotherapy. AIDS-Related Cancers and Their Treatment 2000. [DOI: 10.1201/b14829-15] [Reference Citation Analysis]
79 Behrens G, Dejam A, Schmidt H, Balks H, Brabant G, Körner T, Stoll M, Schmidt RE. Beeinflussung der Glukosetoleranz, B-Zell-Funktion und des Lipid Metabolismus bei HIV-1 infizierten Patienten unter der Therapie mit Proteaseinhibitoren. HIV-Infekt 2000. [DOI: 10.1007/978-3-642-59683-4_67] [Reference Citation Analysis]
80 Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13:2493-505. [PMID: 10630518 DOI: 10.1097/00002030-199912240-00002] [Cited by in Crossref: 295] [Cited by in F6Publishing: 253] [Article Influence: 12.3] [Reference Citation Analysis]
81 Haubrich R, Thompson M, Schooley R, Lang W, Stein A, Sereni D, van der Ende ME, Antunes F, Richman D, Pagano G, Kahl L, Fetter A, Brown DJ, Clumeck N. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team. AIDS 1999;13:2411-20. [PMID: 10597783 DOI: 10.1097/00002030-199912030-00013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.0] [Reference Citation Analysis]
82 Kan VL, Nylen ES. Diabetic ketoacidosis in an HIV patient: a new mechanism of HIV protease inhibitor-induced glucose intolerance. AIDS 1999;13:1987-9. [PMID: 10513665 DOI: 10.1097/00002030-199910010-00029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
83 Shevitz AH, Knox TA, Spiegelman D, Roubenoff R, Gorbach SL, Skolnik PR. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. AIDS 1999;13:1351-7. [PMID: 10449288 DOI: 10.1097/00002030-199907300-00012] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 3.3] [Reference Citation Analysis]
84 Shikuma CM, Waslien C, McKeague J, Baker N, Arakaki M, Cui XW, Souza S, Imrie A, Arakaki R. Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS. AIDS 1999;13:1359-65. [PMID: 10449289 DOI: 10.1097/00002030-199907300-00013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 1.4] [Reference Citation Analysis]
85 Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Körner T, Stoll M, Schmidt RE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-70. [PMID: 10416516 DOI: 10.1097/00002030-199907090-00001] [Cited by in Crossref: 352] [Cited by in F6Publishing: 373] [Article Influence: 14.7] [Reference Citation Analysis]
86 Schmidt HH, Behrens G, Genschel J, Stoll M, Dejam A, Haas R, Manns MP, Schmidt RE. Lipid Evaluation in HIV-1-Positive Patients Treated with Protease Inhibitors. Antiviral Therapy 1999;4:163-170. [DOI: 10.1177/135965359900400305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
87 Ho TT, Chan KC, Wong KH, Lee SS. Indinavir-associated facial lipodystrophy in HIV-infected patients. AIDS Patient Care STDS 1999;13:11-6. [PMID: 11362080 DOI: 10.1089/apc.1999.13.11] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
88 Martínez E, Casamitjana R, Conget I, Gatell JM. Protease inhibitor-associated hyperinsulinaemia. AIDS 1998;12:2077-9. [PMID: 9814880 DOI: 10.1097/00002030-199815000-00023] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 0.7] [Reference Citation Analysis]
89 Walli R, Herfort O, Michl GM, Demant T, Jäger H, Dieterle C, Bogner JR, Landgraf R, Goebel FD. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12:F167-73. [PMID: 9814858 DOI: 10.1097/00002030-199815000-00001] [Cited by in Crossref: 364] [Cited by in F6Publishing: 383] [Article Influence: 14.6] [Reference Citation Analysis]
90 Antiretroviral Therapy and Medical Management of Pediatric HIV Infection. Pediatrics 1998;102:1005-1062. [DOI: 10.1542/peds.102.s4.1005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
91 Bardonnet K, Gil H, Lebrun C, de Wazières B, Dupond J. Diabète sucré au cours des traitements par inhibiteurs des protéases chez le patient infecté par le VIH. La Revue de Médecine Interne 1998;19:675-676. [DOI: 10.1016/s0248-8663(99)80051-4] [Reference Citation Analysis]
92 Alsoub H. Indina Vir-Induced Diabetes Mellitus. Ann Saudi Med 1998;18:333-334. [DOI: 10.5144/0256-4947.1998.333] [Reference Citation Analysis]
93 Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8. [PMID: 9619798 DOI: 10.1097/00002030-199807000-00003] [Cited by in Crossref: 1784] [Cited by in F6Publishing: 1853] [Article Influence: 71.4] [Reference Citation Analysis]
94 Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998;12:F37-9. [PMID: 9583592 DOI: 10.1097/00002030-199806000-00001] [Cited by in Crossref: 202] [Cited by in F6Publishing: 213] [Article Influence: 8.1] [Reference Citation Analysis]
95 &NA;. Indinavir/ritonavir. Reactions Weekly 1997;&NA;:8-9. [DOI: 10.2165/00128415-199706690-00022] [Reference Citation Analysis]